Clinical trial · Interventional
Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years
Multizentrische Therapiestudie Des Multiplen Myeloms DSMM V Therapieoptimierungs-Studie Der Deutschen Studiengruppe Multiples Myelom für Patienten Bis 60 Jahre im Stadium II/III
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is evaluating whether risk-stratification by the means of a chromosomal aberration provides a tool to discriminate between standard and high risk. Risk-adapted therapy is based on allogeneic stem-cell transplantation for high-risk subjects instead of a second autograft in patients with deletion of chromosome 13 who have an HLA-identical stem cell donor available.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| allogeneic stem cell transplant | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- NO_INTERVENTION
- label
- Standard risk IFN
- description
- Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation
- type
- NO_INTERVENTION
- label
- Standard risk PEGIFN
- description
- Maintenance treatment with pegylated interferon following autologous stem cell transplantation
- type
- EXPERIMENTAL
- label
- High risk allo
- description
- Allogeneic stem cell transplantation from an HLA identical related or unrelated donor
- interventionNames
- Biological: allogeneic stem cell transplant
- type
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Primary diagnosis of multiple myeloma * Salmon-and-Durie stage II or III * Less than or equal to 60 years * Signed informed consent Exclusion Criteria: * Relevant comorbidities * Unable to adhere to study protocol * Pregnancy * Not received subject's informed consent
References
Publications (0)
Data not yet available